Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain

Postgraduate Medicine

Volumn 122, Issue 4, 2010, Pages 112-128

  Katz, Nathaniel ^a,b   Hale, Martin ^c   Morris, David ^d   Stauffer, Joseph ^e,f  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Analgesic Solutions   (United States)

^c Gold Coast Research   (United States)

^d WebbWrites   (United States)

^e DURECT Corporation   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic pain; Extended release; Morphine; Opioid withdrawal; Opioids

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN; LORAZEPAM; MORPHINE SULFATE; MORPHINE SULFATE PLUS NALTREXONE; MORPHINE SULFATE WITH SEQUESTERED NALTREXONE; NALTREXONE; NAPROXEN; PARACETAMOL; PLACEBO; TRAMADOL; UNCLASSIFIED DRUG; MORPHINE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTHRALGIA; ARTICLE; BASAL CELL CARCINOMA; BEDTIME DOSAGE; BRIEF PAIN INVENTORY; CHOLELITHIASIS; CHRONIC PAIN; CLINICAL ASSESSMENT; CLINICAL OPIATE WITHDRAWAL SCALE; CONSTIPATION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EXTENDED RELEASE CAPSULE; FEMALE; FUNCTIONAL STATUS; HEADACHE; HIP OSTEOARTHRITIS; HUMAN; HYPOTENSION; INTESTINE OBSTRUCTION; JOINT STIFFNESS; KIDNEY CARCINOMA; KNEE OSTEOARTHRITIS; LUNG CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL OUTCOMES STUDY SLEEP SCALE; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; PANCREATITIS; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PHYSICAL FUNCTION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESTLESS LEGS SYNDROME; RHINORRHEA; SLEEP DISORDER; SLEEP QUALITY; SNORING; SOMNOLENCE; SUBJECTIVE OPIATE WITHDRAWAL SCALE; TREATMENT OUTCOME; VIRAL GASTROENTERITIS; VOMITING; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX; WITHDRAWAL SYNDROME; XEROSTOMIA; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DELAYED RELEASE FORMULATION; MICROCAPSULE; MIDDLE AGED; OSTEOARTHRITIS; PAIN;

ACETAMINOPHEN; ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CAPSULES; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHINE; NALTREXONE; NARCOTIC ANTAGONISTS; OSTEOARTHRITIS; PAIN; PAIN MEASUREMENT; PLACEBOS; TREATMENT OUTCOME;

EID: 77956640307     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.07.2179     Document Type: Article

References (33)

1. Sloan P, Babul N. Extended-release opioids for the management of chronic non-malignant pain. Expert Opin Drug Deliv. 2006;3(4):489-497.
2. Woolf CJ, Hashmi M. Use and abuse of opioid analgesics: potential methods to prevent and deter non-medical consumption of prescription opioids. Curr Opin Invest Drugs. 2004;5(1):61-66.
3. Katz NP, Adams EH, Chilcoat H. et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain. 2007;23(8):648-660.
4. Parsells Kelly J, Cook SF, Kaufman DW, Anderson T, Rosenberg L, Mitchell AA. Prevalence and characteristics of opioid use in the US adult population. Pain. 2008;138(3):507-513.
5. Goodwin JL, Kraemer JJ, Bajwa ZH. The use of opioids in the treatment of osteoarthritis: when, why, and how? Curr Pain Headache Rep. 2005;9(6):390-398.
6. Substance Abuse and Mental Health Services Administration. Results from the 2008 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-36, HHS Publication No. SMA 09-4434, 2009). Rockville, MD. http://www.oas.samhsa.gov/nsduh/2k8nsduh/2k8Results.pdf. Accessed June 9, 2010.
7. Butler SF, Budman SH, Licari A, et al. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf. 2008;17(12):1142-1154.
8. EMBEDA [package insert]. Bristol, TN: King Pharmaceuticals®, Inc.; June 2009.
9. Ross EL, Hahn K. KADIAN (morphine sulfate extended-release) capsules for treatment of chronic, moderate-to-severe, nonmalignant pain. Int J Clin Pract. 2008;62(3):471-479.
10. KADIAN [package insert]. Elizabeth, NJ: Actavis Elizabeth, LLC; February 2009.
11. Johnson F, Jones JB, Stauffer J. Relative bioavailability of plasma naltrexone from crushed ALO-01 (an investigational, abuse-deterrent, extended-release, morphine sulfate formulation with sequestered naltrexone) to a naltrexone oral solution [abstract]. J Pain. 2008;9(4 suppl 2):35.
12. Stauffer J, Setnik B, Sokolowska M, Romach M, Johnson F, Sellers E. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig. 2009;29(12):777-790.
13. Katz NP, Sun S, Johnson FK, Stauffer J. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety. J Pain. 2010;11(4):303-311.
14. Altman RA, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29(8):1039-1049.
15. Altman RA, Alarcón GS, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 1991;34(5):505-514.
16. Lemmens HJ, Wada DR, Munera C, Eltahtawy A, Stanski DR. Enriched analgesic efficacy studies: an assessment by clinical trial simulation. Contemp Clin Trials. 2006;27(2):165-173.
17. McQuay HJ, Derry S, Moore RA, Poulain P, Legout V. Enriched enrollment with randomized withdrawal (EERW): Time for a new look at clinical trial design in chronic pain. Pain. 2008;135(3): 217-220.
18. Katz N, Rauck R, Ahdieh H, et al. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin. 2007;23(1):117-128.
19. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23(2):129-138.
20. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833-1840.
21. Spritzer KL, Hays RD. MOS Sleep Scale: A Manual for Use and Scoring, Version 1.0. Los Angeles, CA: RAND; November 2003.
22. Hays RD, Stewart AL. Sleep measures. In: Stewart A, Ware J, eds. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992:235-259.
23. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
24. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003;35(2):253-259.
25. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13(3):293-308.
26. Farrar JT, Dworkin RH, Max MB. Use of the cumulative proportion of responders analysis graph to present pain data over a range of cut-off points: making clinical trial data more understandable. J Pain Symptom Manage. 2006;31(4):369-377.
27. Hale ME, Ahdieh H, Ma T, Rauck R; Oxymorphone ER Study Group 1. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain. 2007;8(2):175-184.
28. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149-158.
29. Katz N. Methodological issues in clinical trials of opioids for chronic pain. Neurology. 2005;65(12 suppl 4):S32-S49.
30. Nicholson B, Ross E, Sasaki J, Weil A. Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain. Curr Med Res Opin. 2006;22(8):1503-1514.
31. Nicholson B, Ross E, Weil A, Sasaki J, Sacks G. Treatment of chronic moderate-to-severe non-malignant pain with polymer-coated extended-release morphine sulfate capsules. Curr Med Res Opin. 2006;22(3): 539-550.
32. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002;287(5):622-627.
33. Webster L, Jones JB, Johnson F, Sekora D, Stauffer J. Relative drug-liking/euphoria effects of intravenous morphine alone and in combination with naltrexone in recreational opioid users [abstract no. 2993]. Abstract presented at: International Association for the Study of Pain 12th World Congress on Pain; August 17-22, 2008; Glasgow, Scotland.